Rank | Title | Journal | Year | PubWeight™‹?› |
---|---|---|---|---|
1 | Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. | Clin Cancer Res | 2008 | 2.06 |
2 | Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. | Proc Natl Acad Sci U S A | 2010 | 1.67 |
3 | HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. | J Transl Med | 2013 | 1.02 |
4 | A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. | Cancer Immunol Immunother | 2012 | 0.97 |
5 | The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. | Cancer Immunol Immunother | 2013 | 0.89 |